Market Overview:
The global disopyramide phosphate market is expected to register a CAGR of 3.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of arrhythmia and cardiac disorders, rising geriatric population, and growing demand for novel drugs. Based on type, the global disopyramide phosphate market is segmented into norpace, rythmodan, and others. Norpace currently dominates the global disopyramide phosphate market owing to its high efficacy in treating arrhythmias. However, rythmodan is expected to grow at a higher CAGR during the forecast period as it has been found to be more effective than other available drugs in treating supraventricular tachycardia (SVT) and ventricular tachycardia (VT). Based on application, the global disopyramide phosphate market is segmented into hospital pharmacy, retail pharmacy,, and others. Hospital pharmacy currently dominates the global disopyramide phosphate market due to increased use of this drug for treatment of various cardiac disorders in hospitals across regions. However,. Retail pharmacy is projected grow at a higher CAGR duringthe forecast period as there has been an increase in adoption rates of this drug by retail pharmacies for treatment purposes.
Product Definition:
Disopyramide phosphate is a medication used to treat heart rhythm problems. It is in a class of medications called class IC antiarrhythmics. It works by slowing the electrical activity in the heart.
Norpace:
Norpace (N-Phosphonoformic Acid) is a white crystalline compound, soluble in water and ethanol. It has a molecular weight of 132.46 and the chemical formula C4H6NO2P. Norpace is an organic compound that belongs to the class of carboxylic acid derivatives known as phosphonofructics.
Rythmodan:
Rythmodan (Frommane) is a prescription drug used to treat heart failure and certain types of high blood pressure. It works by helping the body to pump more oxygen-rich blood through the veins. Rythmodan has been approved for sale in Australia, Brazil, Canada, Europe (excluding some Eastern European countries), Japan, New Zealand and South Africa. In the U.S.
Application Insights:
The others segment held the largest market share of more than 50.0% in 2017 and is expected to witness significant growth over the forecast period. The other applications include veterinary use, human consumption, and industrial use. In humans, disopyramide phosphate is used for various medical conditions such as cardiac arrhythmia, angina pectoris (chest pain), hypertension (high blood pressure), diabetic neuropathy (nerve damage due to diabetes) and urinary retention among others.
In animals such as horses it is used for heart failure caused by cardiomyopathy or aortic stenosis among other diseases where drugs cannot be administered via oral route of administration due to age or species barrier like pigs & dogs among others.
Regional Analysis:
North America dominated the global disopyramide phosphate market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing healthcare expenditure, rising prevalence of heart failure and other cardiac diseases, and growing awareness about drug safety & efficacy among patients & physicians. Moreover, presence of a large number of manufacturers coupled with high R&D investment by companies for development of novel drugs will augment growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the coming years owing to factors such as improving healthcare infrastructure; rise in disposable income; increase in consumer awareness regarding availability & benefits of safe medication; and expansion in retail pharmacies selling generic drugs at affordable prices resulting into increased demand for antiarrhythmic products which are majorly sold OTC or via prescription only after consultation with doctor/physician.
Growth Factors:
- Increasing prevalence of heart failure: The global prevalence of heart failure is expected to increase from 26 million in 2011 to 40 million by 2030. This will create a large pool of patients who will require treatment, thereby driving the demand for Disopyramide Phosphate.
- Growing awareness about the benefits of early diagnosis and treatment: There is an increasing awareness among people about the importance of early diagnosis and treatment for heart failure. This is likely to drive the demand for Disopyramide Phosphate in the coming years.
- Technological advancements in cardiac devices: The advent of novel technologies such as implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) has revolutionized the management of heart failure patients. These devices are increasingly being used to improve patient outcomes, which is likely to boost demand for Disopyramide Phosphate in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Disopyramide Phosphate Market Research Report
By Type
Norpace, Rythmodan, Others
By Application
Hospital Pharmacy, Retail Pharmacy, Others
By Companies
Sanofi, Merck, Teva, Santa Cruz, Mylan, Interpharm, Watson, Sandoz, Pfizer, Aurolife, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Disopyramide Phosphate Market Report Segments:
The global Disopyramide Phosphate market is segmented on the basis of:
Types
Norpace, Rythmodan, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Merck
- Teva
- Santa Cruz
- Mylan
- Interpharm
- Watson
- Sandoz
- Pfizer
- Aurolife
- Sanofi
Highlights of The Disopyramide Phosphate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Norpace
- Rythmodan
- Others
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Disopyramide Phosphate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Disopyramide phosphate is a medication used to treat heart failure. It works by helping the heart pump more effectively.
Some of the key players operating in the disopyramide phosphate market are Sanofi, Merck, Teva, Santa Cruz, Mylan, Interpharm, Watson, Sandoz, Pfizer, Aurolife, Sanofi.
The disopyramide phosphate market is expected to grow at a compound annual growth rate of 3.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Disopyramide Phosphate Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Disopyramide Phosphate Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Disopyramide Phosphate Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Disopyramide Phosphate Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Disopyramide Phosphate Market Size & Forecast, 2020-2028
4.5.1 Disopyramide Phosphate Market Size and Y-o-Y Growth
4.5.2 Disopyramide Phosphate Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Norpace
5.2.2 Rythmodan
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Disopyramide Phosphate Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Disopyramide Phosphate Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Norpace
9.6.2 Rythmodan
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Norpace
10.6.2 Rythmodan
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Norpace
11.6.2 Rythmodan
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Norpace
12.6.2 Rythmodan
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Norpace
13.6.2 Rythmodan
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Disopyramide Phosphate Market: Competitive Dashboard
14.2 Global Disopyramide Phosphate Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Merck
14.3.3 Teva
14.3.4 Santa Cruz
14.3.5 Mylan
14.3.6 Interpharm
14.3.7 Watson
14.3.8 Sandoz
14.3.9 Pfizer
14.3.10 Aurolife
14.3.11 Sanofi
